Abstract
The Annexin A11 (ANXA11) gene has recently emerged as a causative factor in amyotrophic lateral sclerosis (ALS), with or without frontotemporal dementia (FTD). This study investigates ANXA11 mutations within a Chinese cohort of ten patients presenting with ALS-FTD or behavioral variant FTD (bv-FTD). Through Next-Generation Sequencing (NGS), we identified a heterozygous p.D40G mutation in a patient with ALS-FTD. This finding is significant as the p.D40G variant was previously associated exclusively with ALS. Our results expand the clinical phenotype of ANXA11 mutations and underscore the genetic heterogeneity of the ALS-FTD spectrum.
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are now recognized as two ends of a single pathological continuum, often referred to as the ALS-FTD spectrum. While several genes, such as C9orf72 and TARDBP, have been identified as major contributors, the genetic basis for many cases remains elusive. The ANXA11 gene, which encodes a calcium-dependent phospholipid-binding protein, was recently linked to ALS. However, its role in the combined ALS-FTD phenotype, particularly in non-European populations, requires further elucidation. This study aims to characterize ANXA11 mutations and their associated clinical presentations in a Chinese patient cohort.
Methodology
The study included ten probands from the Department of Neurology at the China-Japan Friendship Hospital in Beijing, suspected of having ALS-FTD or bv-FTD. A multi-layered diagnostic approach was employed:
- Genetic Analysis: Whole-exome sequencing (WES) via NGS was performed, followed by Sanger sequencing for validation. Variants were filtered against global databases (gnomAD, 1000 Genomes) to identify rare, potentially pathogenic mutations.
- Neuroimaging: Patients underwent 3.0T MRI and 18F-AV45-PET imaging to assess brain atrophy and rule out amyloid-beta deposits characteristic of Alzheimer’s disease.
- Clinical Assessment: Comprehensive neuropsychological testing (MMSE, MoCA) and needle electromyography (EMG) were conducted to evaluate cognitive deficits and motor neuron involvement.
Results
Among the ten probands, six presented with ALS-FTD and four with bv-FTD. A non-synonymous heterozygous mutation (c.119A>G, p.D40G) in ANXA11 was identified in Proband 1.
Clinical Presentation of Proband 1
Proband 1 initially exhibited behavioral changes, including impulsivity and loss of social decorum, followed by the development of upper motor neuron disease symptoms, such as limb weakness. Neuropsychological testing confirmed significant cognitive impairment.
Neuroimaging Findings
MRI scans of Proband 1 revealed marked bilateral temporal lobe atrophy. Additionally, fluid-attenuated inversion recovery (FLAIR) sequences showed bilateral hyperintensities along the corticospinal tracts, a hallmark of motor system involvement. 18F-AV45-PET imaging was negative for amyloid deposits, confirming that the cognitive decline was attributable to FTD pathology rather than Alzheimer's disease.
Discussion
The identification of the p.D40G mutation in an ALS-FTD patient is a pivotal finding. Previously linked only to pure ALS, this discovery demonstrates the phenotypic plasticity of ANXA11 mutations—where the same genetic variant can lead to diverse clinical outcomes affecting either motor neurons, cortical neurons, or both.
The p.D40G mutation is located in the N-terminal region of the Annexin A11 protein, near the calcyclin-binding domain. Annexin A11 plays a crucial role in proteostasis, facilitating the clearance of protein aggregates. Mutations in this region likely disrupt protein-protein interactions, leading to the accumulation of toxic aggregates that drive neurodegeneration. A literature review of 32 known ANXA11 variants suggests that mutations in the long N-terminus are more frequently associated with the combined ALS-FTD phenotype.
Conclusion
This study confirms that ANXA11 mutations contribute to the genetic landscape of ALS-FTD in the Chinese population. The discovery of the p.D40G mutation in an ALS-FTD context highlights the complex genotype-phenotype correlations inherent in this disease spectrum. These findings provide a foundation for future research into targeted therapies and emphasize the importance of genetic screening in patients presenting with overlapping motor and cognitive symptoms.
Summary updated